

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

AGILA SPECIALTIES INC. and MYLAN LABORATORIES LIMITED,  
*Petitioners*

v.

CEPHALON, INC.  
*Patent Owner*

---

Case IPR2016-00026  
Patent No. 8,791,270

---

**PATENT OWNER'S UPDATED MANDATORY NOTICES  
PURSUANT TO 37 C.F.R. § 42.8**

**Mail Stop "PATENT BOARD"**  
Patent Trial and Appeal Board  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Pursuant to 37 C.F.R. § 42.8(a)(3), (b)(2), (b)(3), and (b)(4), Patent Owner, Cephalon, Inc. ("Cephalon"), hereby submits the following updated mandatory notices.

**I. RELATED MATTERS (37 C.F.R. § 42.8(b)(2))**

**A. Judicial Matters**

U.S. Patent No. 8,791,270 ("270 Patent") has been or is currently at issue in the following district court litigation:

- *Cephalon, Inc. v. Apotex, Inc.*, No. 1:15-cv-00404-GMS (D. Del.);
- *Cephalon, Inc. v. Panacea Biotec, Ltd.*, No. 1:15-cv-00735-GMS (D. Del.);
- *Cephalon, Inc. v. Nang Kuang Pharm. Co., Ltd.*, 1:14-cv-01117-GMS (D. Del.); and
- *Cephalon, Inc. v. Nang Kuang Pharm. Co., Ltd.*, No. 1:14-cv-05180-KAM-RER (E.D.N.Y.).

Additionally, the following Delaware district court litigations involving the '270 Patent (and/or related patents) were consolidated into *In re Bendamustine Consol. Cases*, No. 1:13-cv-02046-GMS (D. Del.):

- *Cephalon Inc. v. Eagle Pharms. Inc.*, No. 1:13-cv-01738-GMS (D. Del.);

- *Cephalon Inc. v. Hetero Labs Ltd.*, 1:13-cv-02046-GMS (D. Del.);
- *Cephalon Inc. v. Agila Specialties Inc.*, 1:13-cv-02080-GMS (D. Del.);
- *Cephalon Inc. v. InnoPharma Inc.*, No. 1:13-cv-02081-GMS (D. Del.);
- *Cephalon, Inc. v. Dr. Reddy's Labs., Ltd.*, No. 1:13-cv-02082-GMS (D. Del.);
- *Cephalon, Inc. v. Glenmark Pharms. Ltd.*, No. 1:13-cv-02093-GMS (D. Del.);
- *Cephalon Inc. v. Hospira Inc.*, No. 1:13-cv-02094-GMS (D. Del.);
- *Cephalon, Inc. v. Accord Healthcare, Inc.*, 1:13-cv-02095-GMS (D. Del.);
- *Cephalon, Inc. v. Sun Pharma Global FZE*, No. 1:13-cv-02096-GMS (D. Del.);
- *Cephalon Inc. v. Sandoz Inc.*, No. 1:13-cv-02104-GMS (D. Del.);
- *Cephalon, Inc. v. Actavis LLC f/k/a Actavis Inc.*, 1:14-cv-00122-GMS (D. Del.);
- *Cephalon, Inc. v. Sun Pharma Global FZE*, No. 1:14-cv-00333-GMS (D. Del.);

- *Cephalon, Inc. v. Dr. Reddy's Labs., Ltd.*, No. 1:14- cv-00334-GMS (D. Del.);
- *Cephalon, Inc. v. Emcure Pharms., Ltd.*, No. 1:14-cv-00335-GMS (D. Del.);
- *Cephalon, Inc. v. Pharmasci. Inc.*, 1:14-cv-00568-GMS (D. Del.);
- *Cephalon Inc. v. InnoPharma Inc.*, No. 1:14-cv-00590-GMS (D. Del.);
- *Cephalon, Inc. v. Breckenridge Pharm., Inc.*, 1:14-cv-00671-GMS (D. Del.);
- *Cephalon Inc. v. Eagle Pharms. Inc.*, No. 1:14-cv-01042-GMS (D. Del.);
- *Cephalon, Inc. v. Eurohealth Int'l Sarl*, 1:14-cv-01045-GMS (D. Del.);
- *Cephalon, Inc. v. Sagent Pharms, Inc.*, 1:14-cv-01116-GMS (D. Del.);
- *Cephalon, Inc. v. Agila Specialties, Inc.*, No. 1:14-cv-01237-GMS (D. Del.);
- *Cephalon Inc. v. InnoPharma Inc.*, No. 1:14-cv-01238-GMS (D. Del.);
- *Cephalon Inc. v. Sandoz Inc.*, 1:14-cv-01239-GMS (D. Del.);

- *Cephalon, Inc. v. Dr. Reddy's Labs., Ltd.*, No. 1:14-cv-01241-GMS (D. Del.);
- *Cephalon Inc. v. Hospira Inc.*, No. 1:14-cv-01242-GMS (D. Del.);
- *Cephalon, Inc. v. Sun Pharma Global FZE*, No. 1:14-cv-01243-GMS (D. Del.);
- *Cephalon, Inc. v. Wockhardt Bio Ltd.*, 1:14-cv-01332-GMS (D. Del.);
- *Cephalon Inc. v. Sandoz Inc.*, No. 1:15-cv-00178-GMS (D. Del.); and
- *Cephalon, Inc. v. Dr. Reddy's Labs., Ltd.*, No. 15-cv-00179-GMS (D. Del.).

**B. Administrative**

The '270 Patent is the subject of a petition for *Inter Partes* Review in IPR2016-00098. The Board has not yet decided whether to institute review on that petition.

The '270 Patent claims priority to U.S. Patent No. 8,436,190, which was at issue in IPR2015-00503, now settled.

The '270 Patent also claims priority to U.S. Patent No. 8,461,350 and U.S. Provisional Patent Application No. 60/644,354. U.S. Patent Nos. 8,895,756, 8,436,190 and 8,609,863 also claim priority to U.S. Provisional Patent Application No. 60/644,354.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.